title: Regulators of Glucose Metabolism in CD4+and CD8+T Cells.
abstract: Much like cancer cells, activated T cells undergo various metabolic changes that allow them to grow and proliferate rapidly. By adopting aerobic glycolysis upon activation, T cells effectively prioritize efficiency in biosynthesis over energy generation. There are distinct differences in the way CD4+and CD8+T cells process activation signals. CD8+effector T cells are less dependent on Glut1 and oxygen levels compared to their CD4+counterparts. Similarly the downstream signaling by TCR also differs in both effector T cell types. Recent studies have explored PI3K/Akt, mTORC, HIF1α, p70S6K and Bcl-6 signaling in depth providing definition of the crucial roles of these regulators in glucose metabolism. These new insights may allow improved therapeutic manipulation against inflammatory conditions that are associated with dysfunctional T-cell metabolism such as autoimmune disorders, metabolic syndrome, HIV, and cancers.
authors.affiliation: a Centre for Biomedical Research, Burnet Institute , Melbourne , Australia.|b Department of Infectious Diseases , Monash University , Melbourne , Australia.
authors.forename: Clovis S
authors.initials: CS
authors.lastname: Palmer
authors.affiliation: a Centre for Biomedical Research, Burnet Institute , Melbourne , Australia.
authors.forename: Tabinda
authors.initials: T
authors.lastname: Hussain
authors.affiliation: c Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Facultad de Medicina , Buenos Aires , Argentina.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Duette
authors.affiliation: d Department of Immunology , Monash University , Melbourne , Australia.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Weller
authors.affiliation: c Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Facultad de Medicina , Buenos Aires , Argentina.
authors.forename: Matias
authors.initials: M
authors.lastname: Ostrowski
authors.affiliation: e Laboratory of Integrative Immunology, National Institute of Respiratory Diseases Ismael CosÃ-o Villegas , Mexico City , Mexico.
authors.forename: Isabel
authors.initials: I
authors.lastname: Sada-Ovalle
authors.affiliation: a Centre for Biomedical Research, Burnet Institute , Melbourne , Australia.|b Department of Infectious Diseases , Monash University , Melbourne , Australia.|f Infectious Diseases Department , The Alfred Hospital , Melbourne , Australia.
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Crowe
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism*; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism*; D051272:Glucose Transporter Type 1 / Q000378:metabolism; D006019:Glycolysis / Q000187:drug effects / Q000276:immunology*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000037:antagonists & inhibitors / Q000378:metabolism; D008213:Lymphocyte Activation; D000076222:Mechanistic Target of Rapamycin Complex 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D024821:Metabolic Syndrome / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism; D051560:Proto-Oncogene Proteins c-bcl-6 / Q000378:metabolism; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000378:metabolism; D015398:Signal Transduction / Q000276:immunology*
chemical_list: D000970:Antineoplastic Agents; D005947:Glucose; D051272:Glucose Transporter Type 1; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D000076222:Mechanistic Target of Rapamycin Complex 1; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D051560:Proto-Oncogene Proteins c-bcl-6; D038762:Ribosomal Protein S6 Kinases, 70-kDa; C084103:BCL6 protein, human; C495677:SLC2A1 protein, human
keywords: Akt; Bcl-6; Glut1; HIF1α; PDK-1; PI3K; T cells; T-cell activation; glucose; mTORC